Table 1. Baseline Characteristics and Outcomes Among Study Participants by Cohort and Self-reported Race Group.
| Source | Participant race | No. | Age, mean (SD), y | Female, % | Mean (SD), mL | Kidney failure requiring treatment | All-cause mortality | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| eGFRcr | eGFRcys | eGFRcr-cys | ||||||||||
| Age, sex, and race | Age and sex | Age and sex | Age and sex | Follow-up, mean (SD), y | 5-y risk, % | Follow-up, mean (SD), y | 5-y risk, % | |||||
| General population | ||||||||||||
| ARIC | Black | 2484 | 62 (6) | 64 | 92 (21) | 83 (18) | 89 (19) | 89 (18) | 21.0 (2.7) | 0.65 (0.40-1.05) | 17.2 (6.0) | 6.1 (5.2-7.1) |
| Non-Black | 8731 | 63 (6) | 53 | 85 (14) | 89 (14) | 83 (18) | 89 (14) | 21.3 (1.7) | 0.31 (0.21-0.45) | 17.8 (5.6) | 5.1 (4.6-5.6) | |
| CHS | Black | 495 | 77 (5) | 65 | 71 (19) | 66 (17) | 69 (20) | 70 (19) | 10.7 (5.4) | 19.4 (16.2-23.2) | ||
| Non-Black | 2489 | 78 (5) | 58 | 65 (16) | 69 (16) | 65 (18) | 69 (17) | 10.0 (5.4) | 22.5 (20.9-24.2) | |||
| MESA | Black | 1846 | 62 (10) | 55 | 86 (19) | 79 (16) | 90 (20) | 88 (18) | 12.7 (3.3) | 4.9 (4.0-6.0) | ||
| Non-Black | 4848 | 62 (10) | 52 | 82 (15) | 86 (15) | 89 (20) | 91 (17) | 13.2 (3.0) | 3.4 (2.9-3.9) | |||
| NHANES III | Black | 1742 | 51 (20) | 52 | 96 (29) | 86 (25) | 98 (27) | 95 (26) | 18.0 (7.8) | 9.9 (8.6-11.4) | ||
| Non-Black | 5280 | 59 (20) | 53 | 86 (24) | 90 (23) | 88 (28) | 92 (26) | 16.5 (8.1) | 12.7 (11.8-13.6) | |||
| REGARDS | Black | 11 506 | 65 (9) | 61 | 88 (24) | 80 (21) | 79 (24) | 82 (23) | 11.3 (3.6) | 1.62 (1.40-1.88) | 11.9 (3.8) | 9.0 (8.5-9.5) |
| Non-Black | 16 669 | 66 (9) | 50 | 82 (17) | 86 (17) | 77 (22) | 84 (20) | 11.4 (3.4) | 0.36 (0.27-0.46) | 12.0 (3.6) | 8.0 (7.6-8.4) | |
| Overall | Black | 18 073 | 63 (11) | 60 | 89 (24) | 81 (21) | 83 (24) | 85 (22) | 12.7 (5.2) | 1.47 (1.28-1.68) | 13.2 (5.2) | 8.6 (8.2-9.0) |
| Non-Black | 38 017 | 65 (12) | 52 | 82 (18) | 86 (18) | 81 (23) | 86 (20) | 14.0 (5.9) | 0.41 (0.34-0.50) | 14.0 (5.7) | 8.3 (8.1-8.6) | |
| CKD population | ||||||||||||
| AASK | Black | 949 | 55 (11) | 39 | 46 (15) | 42 (13) | 48 (18) | 45 (15) | 7.4 (3.4) | 16.5 (14.3-19.1) | 7.7 (3.4) | 9.3 (7.5-11.4) |
| CRIC | Black | 1650 | 58 (11) | 51 | 44 (15) | 40 (13) | 51 (23) | 46 (18) | 8.0 (4.5) | 22.7 (20.7-24.9) | 9.8 (4.1) | 14.4 (12.8-16.2) |
| Non-Black | 2277 | 58 (11) | 41 | 45 (15) | 47 (16) | 54 (24) | 51 (20) | 8.8 (4.4) | 15.7 (14.2-17.3) | 10.1 (3.7) | 11.2 (10.0-12.6) | |
| MDRD | Black | 101 | 50 (12) | 44 | 36 (17) | 33 (15) | 35 (16) | 33 (15) | 7.7 (6.0) | 37.0 (28.2-47.4) | 13.4 (5.4) | 9.9 (5.5-17.6) |
| Non-Black | 944 | 52 (13) | 39 | 35 (15) | 36 (16) | 32 (14) | 33 (15) | 7.8 (5.7) | 39.3 (36.2-42.5) | 14.1 (5.0) | 8.1 (6.5-10.0) | |
| Overall | Black | 2700 | 56 (11) | 47 | 44 (15) | 38 (13) | 49 (21) | 45 (17) | 7.8 (4.2) | 21.1 (19.5-22.7) | 9.2 (4.1) | 12.5 (11.3-13.9) |
| Non-Black | 3221 | 56 (12) | 40 | 42 (16) | 44 (16) | 47 (24) | 46 (20) | 8.5 (4.8) | 22.8 (21.3-24.3) | 11.3 (4.5) | 10.3 (9.3-11.4) | |
| Populations combined | ||||||||||||
| Overall | Black | 20 773 | 62 (11) | 59 | 83 (27) | 72 (23) | 79 (26) | 80 (26) | 12.0 (5.3) | 7.3 (6.9-7.7) | 12.7 (5.3) | 9.1 (8.7-9.5) |
| Non-Black | 41 238 | 64 (12) | 51 | 79 (21) | 83 (21) | 78 (24) | 83 (23) | 13.4 (6.0) | 3.9 (3.7-4.1) | 13.8 (5.6) | 8.5 (8.2-8.8) | |
Abbreviations: AASK, African American Study of Kidney Disease and Hypertension; ARIC, Atherosclerosis Risk in Communities; CHS, Cardiovascular Health Study; CKD, chronic kidney disease; CRIC, Chronic Renal Insufficiency Cohort; cr, creatinine; cys, cystatin; eGFR, estimated glomerular filtration rate; MESA, Multi-Ethnic Study of Atherosclerosis; MDRD, Modification of Diet in Renal Disease; NHANES, National Health and Nutrition Examination Survey III; REGARDS, Reasons for Geographic and Racial Differences in Stroke.